FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications
Audience: Health Care Professional, Consumer January 13, 2026
FDA Evaluation Did Not Identify an Increased Risk of Suicidal Ideation or Behavior With the Use of GLP-1 RA Medications
This information is an update to the FDA Drug Safety…
Food Companies Are Targeting Users of Weight-Loss Drugs With ‘GLP-1 Friendly’ Labels
(MedPage Today) — Meals and snacks with “GLP-1 Friendly” labels on the packaging are becoming more common in U.S. supermarkets as a growing number of Americans try obesity drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) to lose weight…
GLP-1 medications: A comprehensive overview
With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.
Hormone therapy combined with tirzepatide linked to greater weight loss after menopause
A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, a Food and Drug Administration-approved drug for the treatment of overweight and obesity. The findings, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, could expand treatment possibilities for millions of women struggling with obesity and obesity-related diseases after menopause.
What’s next for GLP-1s?
Now that GLP-1 drugs have revolutionized how millions of Americans treat obesity and Type 2 diabetes, scientists are exploring the benefits of using the drugs for a host of other chronic diseases—many with few treatment options—such as heart failure, chronic liver disease, obstructive sleep apnea, and even substance use disorders.
Gordon Ramsay slams ‘stupid’ Ozempic-inspired restaurant menu trend
Gordon Ramsay, celebrity chef, slams restaurants for creating Mounjaro-minded menus, calling the GLP-1-inspired dining trend “stupid” and “embarrassing.”
Redefining Obesity Treatment Beyond GLP-1 Limits
In this episode of Denatured, you’ll be listening to Jane Hughes, President of R&D and Co-founder of Verdiva Bio, and Jon Rees, CEO and Co-founder of MitoRx Therapeutics. We’ll discuss next-generation obesity solutions tackling GLP-1’s muscle loss and adherence challenges, through innovative muscle preservation, oral administration and combination therapy.
Opinion: My biggest GLP-1 ethical problem: patients who don’t want to stop
Some GLP-1 patients are begging to stay on the drugs just a little bit longer, presenting an ethical dilemma for doctors.
Risk for Nonscarring Hair Loss Increased in Association With GLP-1 Receptor Agonist Use
WEDNESDAY, Feb. 18, 2026 — The risk for nonscarring hair loss (NSHL) is increased in association with glucagon-like peptide-1 receptor agonist (GLP-1 RA) use, according to a study published online Feb. 9 in the Journal of the American Academy of…
GLP-1s Bringing Back Scurvy? Achondroplasia Drug Win; Intermittent Fasting Flop
(MedPage Today) — The meteoric rise of GLP-1 drugs for weight loss has raised concerns about potential malnutrition and even the comeback of scurvy. (The Hill)
An $80-per-month produce prescription subsidy failed to improve cardiometabolic health…